Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Posted on by ScienceFather

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

 Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

 

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

 

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

 

Publication top noted
  • Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
    Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
    Year: 2024
    Citations: 0
  • Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
    Year: 2024
    Citations: 0
  • Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
    Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2024
    Citations: 2
  • Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
    Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
    Year: 2024
    Citations: 3
  • Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
    Authors: Pozzi, S., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
    Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
    Year: 2024
    Citations: 0
  • Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2023
    Citations: 6
  • Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
    Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
    Year: 2023
    Citations: 4
  • Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
    Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
    Year: 2023
    Citations: 6

Shailaja Jadhav | Pharmaceutics | Women Researcher Award

Posted on by ScienceFather

Mrs. Shailaja Jadhav | Pharmaceutics | Women Researcher Award

Assistant Professor at Gourishankar Institute of Pharmaceutical Education and Research Limb, Satara, India.

Mrs. Shailaja Vishal Jadhav is a dedicated researcher and academic in the field of pharmaceutical sciences, with a focus on advanced drug delivery systems and nanotechnology. Currently pursuing her Ph.D., she has demonstrated a strong commitment to research and education, holding an assistant professor position and contributing to her field through publications and presentations. Her work is recognized nationally, and she continues to push the boundaries of pharmaceutical research with her innovative approaches.

Profile:

Education

Mrs. Jadhav holds a Bachelor’s degree in Pharmacy (B. Pharm) and a Master’s degree in Pharmacy (M. Pharm) from Shivaji University, Kolhapur. She is currently pursuing her Ph.D. at the Government College of Pharmacy, Karad, under Shivaji University, where she has submitted her final thesis, awaiting her viva examination. Her solid academic foundation is reflected in her consistent academic performance, with notable scores during her undergraduate and postgraduate studies.

 

Professional Experiences 

Mrs. Jadhav brings a wealth of both academic and industrial experience to her career. She has accumulated over eight years of teaching experience, including five years as an Assistant Professor at the Gourishankar Institute of Pharmaceutical Education and Research in Satara. Additionally, she has undergone industrial training at Meditab Specialities Pvt. Ltd., where she gained practical exposure to pharmaceutical processes. This combination of academic instruction and hands-on experience in the industry has enriched her practical and theoretical knowledge in pharmaceutical sciences.

Research Interests

Mrs. Shailaja Vishal Jadhav’s research interests are primarily focused on Novel Drug Delivery Systems (NDDS), formulation and development, and nanotechnology. She is passionate about exploring innovative approaches to improve the efficacy and safety of drug delivery. Her Ph.D. research revolves around the extraction and quantification of bioactive compounds, specifically focusing on Supercritical CO2 Extraction and the pharmacological screening of Steroidal Saponins from natural sources. Additionally, her interest in nanotechnology aims at developing nanoscale drug delivery methods that can enhance targeted therapies and minimize side effects, making her work highly relevant in the fields of pharmaceutical and biomedical sciences.

 

Research skills 

Her research expertise lies in Novel Drug Delivery Systems (NDDS), formulation and development, and nanotechnology. She is proficient in using sophisticated laboratory instruments such as HPLC, UV/Visible spectrophotometer, and particle size analyzers, which are critical for her research. Her Ph.D. research focuses on supercritical CO2 extraction and steroidal saponins, reflecting her skills in both cutting-edge extraction techniques and pharmacological screening. Her ability to combine advanced scientific methods with real-world applications makes her a strong asset to the research community.

 

Award And Recoginition 

Mrs. Jadhav has received multiple awards and recognitions throughout her academic journey. Most notably, she was awarded the prestigious Chhatrapati Shahu Maharaj National Research Fellowship (CSMNRF-2020) by the Government of Maharashtra for her Ph.D. research. She secured the 3rd rank in the Shivaji University Ph.D. Entrance Examination and achieved 2nd place in an international symposium poster presentation. Her research work has also been published in a high-impact journal, underscoring the quality and significance of her contributions to pharmaceutical science.

 

Conclusion

Mrs. Shailaja Vishal Jadhav’s academic qualifications, research achievements, and diverse professional experience make her a strong candidate for the Research for Women Researcher Award. Her current Ph.D. pursuit, national fellowship, and publication record demonstrate her potential for significant contributions to her field. Finalizing her Ph.D. and expanding her research outputs could further elevate her candidacy.

 

Publication Top Notes
  • Title: Natural Polymer-Based Formulation and Characterization of Matrix-Controlled Release Tablet of Losartan Potassium Employing Sintering Technique
    Authors: Dr. A. S. Kulkarni, S. V. Jadhav*, Dr. N. H. Aloorkar
    Year: 2019
    Citation: European Journal of Biomedical and Pharmaceutical Sciences, Volume 6, Issue 10, 312-322
    📅💊🌿
  • Title: Phytoconstituents Based Nanomedicines for the Management of Diabetes: A Review
    Authors: Shailaja Jadhav*, Dr. Adhikarao Yadav
    Year: 2023
    Citation: Pharmaceutical Nanotechnology, Bentham Science Publisher, Volume 11, Issue 3, 217-237. DOI: 10.2174/2211738511666230118095936
    🌱🧪🔬
  • Title: Supercritical CO2 Extraction, Quantification, and Pharmacological Screening of Steroidal Saponins from Fruits of Momordica Charantia L
    Authors: Shailaja Jadhav*, Adhikrao Yadav
    Year: 2023
    Citation: International Journal of Pharmaceutical Quality Assurance, Volume 14, Issue 3, July-September, 563-572
    🍈💧⚗️
  • Title: Molecular Docking Studies of Antidiabetic Biomolecule Charantin Isolated from Fruits of Momordica Charantia L
    Authors: Shailaja Jadhav*, Adhikrao Yadav
    Year: 2024
    Citation: Advances in Bioresearch, Volume 15, Issue 2, March 2024, 182-189. DOI: 10.15515/abr.0976-4585.15.2.182189
    🧬🔍🧫
  • Title: Enhanced Antidiabetic Performance Through Optimized Charantin-Loaded Nanostructured Lipid Carriers: Formulation and In Vivo Studies in Diabetic Mice
    Authors: Shailaja Jadhav*, Dr. Adhikarao Yadav, Sameer Nadaf
    Year: 2024
    Citation: Journal of Drug Delivery Science and Technology. DOI: 10.1016/j.jddst.2024.106208
    🧑‍🔬🐭💉

Long Chen | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Long Chen | Pharmaceutical Science | Best Researcher Award

Assistant Professor, Peking University Third Hospital, China

Long Chen is a prominent researcher recognized for his impactful contributions in oncology and drug delivery systems. With 17 publications since 2015 and an impressive H-index of 39, his work has garnered 715 total citations, reflecting significant influence in the scientific community. His recent studies focus on critical challenges such as drug resistance in cancer therapies, showcasing his engagement with pressing medical issues. Chen’s research is characterized by a diverse range of innovative topics, enhancing the relevance of his work in contemporary science. While his individual contributions are substantial, fostering broader collaborations and increasing public engagement could further amplify his impact. Overall, Long Chen’s impressive publication record, high citation metrics, and dedication to advancing cancer research position him as a strong candidate for the Best Researcher Award, highlighting his potential for continued contributions to the field.

Profile:

Education

Long Chen obtained his Ph.D. in Biomedical Engineering from a prestigious institution, where he focused on advanced therapeutic strategies and drug delivery systems. His academic journey began with a Bachelor’s degree in Chemical Engineering, which laid a solid foundation in both theoretical and practical aspects of the field. Chen furthered his education with a Master’s degree in Pharmaceutical Sciences, enhancing his expertise in drug formulation and development. Throughout his studies, he engaged in various research projects, collaborating with multidisciplinary teams to explore innovative approaches in cancer therapy and nanomedicine. This strong educational background, coupled with hands-on research experience, has equipped Long Chen with the skills necessary to address complex challenges in biomedical research and significantly contribute to advancements in healthcare. His commitment to lifelong learning and continuous improvement is evident in his pursuit of knowledge across multiple domains within his field.

Professional Experience

Long Chen has accumulated significant professional experience in the field of biomedical research, focusing primarily on cancer therapy and drug delivery systems. He has held key research positions that emphasize his expertise in developing innovative therapeutic strategies and biomaterials. His recent work includes exploring the mechanisms of drug resistance in hepatocellular carcinoma and the design of protein-based nanoparticles for targeted cancer treatment. Chen has published extensively in high-impact journals, showcasing his findings and contributing to the scientific community’s understanding of complex biological processes. Additionally, he has been involved in collaborations that bridge basic research and clinical applications, enhancing the translational potential of his work. His role in various projects has not only solidified his reputation as a leading researcher but also allowed him to mentor emerging scientists in the field, further contributing to the growth of biomedical research and its applications in healthcare.

Research Skills

Long Chen possesses a diverse and robust set of research skills that have significantly contributed to his field. His expertise in drug synthesis and delivery is evident through his innovative work on nanomedicine and targeted therapeutics, which aims to improve cancer treatment efficacy. Proficient in advanced techniques such as protein engineering and bioorthogonal chemistry, he has successfully developed novel therapeutic platforms, including self-assembled nanoparticles and prodrug-antibody conjugates. His strong analytical skills are reflected in his ability to conduct rigorous experimental studies and publish in high-impact journals. Furthermore, Chen’s familiarity with computational modeling enhances his research by allowing for precise predictions of drug interactions and biological responses. With a solid foundation in interdisciplinary collaboration, he effectively integrates knowledge from chemistry, biology, and medicine, positioning himself as a leader in advancing therapeutic strategies against complex diseases. Overall, his research skills are critical to addressing pressing challenges in modern healthcare.

Award and Recognition

Long Chen has garnered significant recognition for his impactful contributions to cancer research and drug delivery systems. His innovative work has led to numerous publications in high-impact journals, reflecting his expertise in areas such as biomaterials and therapeutic development. Notably, his H-index of 39 indicates a substantial citation impact, underscoring the influence of his research within the scientific community. Additionally, Long’s work has been cited in various patents, demonstrating the practical applications of his findings in real-world scenarios. His recent publications address critical challenges in oncology, including drug resistance and targeted therapies, showcasing his commitment to advancing medical science. Long Chen’s achievements highlight his role as a leader in his field, making him a deserving candidate for prestigious awards that recognize excellence in research and innovation. His continued contributions promise to further enhance his reputation and impact in the scientific landscape.

Conclusion

In conclusion, Long Chen stands out as a prominent researcher deserving of the Best Researcher Award due to his impressive publication record and significant impact on the scientific community. With 17 publications in reputable journals and an H-index of 39, his work in areas such as cancer therapy and drug delivery systems highlights his expertise and relevance in contemporary research. The diversity of his topics, coupled with recent contributions addressing critical challenges like drug resistance, underscores his innovative approach. Furthermore, the citations from patents indicate the practical implications of his research, showcasing its applicability in real-world scenarios. By enhancing collaborations and engaging more with the public, Long Chen has the potential to further amplify his impact. Overall, his robust academic achievements and commitment to advancing knowledge make him a compelling candidate for this prestigious award.

Publication Top Notes

  • Title: Nanoalbumin–prodrug conjugates prepared via a thiolation‐and‐conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T‐cell infiltration
    Authors: Long Chen, Nuo Xu, Pan Wang, Haichuan Zhu, Zijian Zhang, Zhanqun Yang, Wenyuan Zhang, Hongyan Guo, Jian Lin
    Journal: Bioengineering & Translational Medicine
    Year: 2023
    Citations: Not available yet
    DOI: 10.1002/btm2.10377
  • Title: LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB)
    Authors: Xi Shi, Zihao Wang, Wei Ren, Long Chen, Cong Xu, Menghua Li, Shiyong Fan, Yuru Xu, Mengbing Chen, Fanjun Zheng et al.
    Journal: Signal Transduction and Targeted Therapy
    Year: 2022
    Citations: Not available yet
    DOI: 10.1038/s41392-022-00995-z
  • Title: Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants
    Authors: Yu Han, Zhenlin Yang, Hengrui Hu, Heng Zhang, Long Chen, Kexin Li, Linghao Kong, Qianran Wang, Bo Liu, Manli Wang et al.
    Journal: Journal of the American Chemical Society
    Year: 2022
    Citations: Not available yet
    DOI: 10.1021/jacs.1c11554
  • Title: A Ferritin–Albumin–Cu Nanoparticle that Efficaciously Delivers Copper(II) Ions to a Tumor and Improves the Therapeutic Efficacy of Disulfiram
    Authors: Nuo Xu, Yuan-Fan Yang, Long Chen, Jian Lin
    Journal: ACS Omega
    Year: 2020
    Citations: Not available yet
    DOI: 10.1021/acsomega.0c00293
  • Title: Blood–Brain Barrier- and Blood–Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases
    Authors: Long Chen, Dan Zeng, Nuo Xu, Chengpeng Li, Wenyuan Zhang, Xinjie Zhu, Yan Gao, Peng R. Chen, Jian Lin
    Journal: ACS Applied Materials & Interfaces
    Year: 2019
    Citations: Not available yet
    DOI: 10.1021/acsami.9b14046

 

Mohammad Hossein Boskabady | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Dr. Mohammad Hossein Boskabady | Pharmacology | Best Researcher Award

Professor of Clinical Physiology, Mashhad University of Medical Sciences, Iran

Dr. Mohammad Hossein Boskabady is a distinguished researcher in the field of Pharmacology, renowned for his innovative contributions and groundbreaking research. With a strong background in pharmacological sciences, Dr. Boskabady’s work focuses on exploring the therapeutic potentials and mechanisms of various compounds. His extensive research has significantly advanced the understanding of drug actions and interactions, earning him recognition as a leading figure in pharmacological research. Dr. Boskabady’s commitment to scientific excellence and his impactful discoveries make him a deserving candidate for the Best Researcher Award.

Profile

Education 

Dr. Mohammad Hossein Boskabady’s academic journey began with his primary education in Boskabad, Khorasan, followed by high school in Gonabad, Khorasan, Iran. He earned his M.D. from Mashhad University of Medical Sciences. Dr. Boskabady furthered his studies as a postgraduate student in Physiology at University College London before completing his Ph.D. in Medicine at Charing Cross and Westminster Medical School, where he focused his thesis on the responsiveness of human bronchi to pharmacological agonists and antagonists. With a strong commitment to advancing pharmacological research, Dr. Boskabady aims to continue his research and lecturing at the university level, contributing to the field through innovative studies and academic excellence.

Employment

Dr. Mohammad Hossein Boskabady’s professional career began as a Doctor in the Emergency and Casualty Department at Imam Reza Hospital in Mashhad, Iran. Concurrently, he served as a Lecturer in Clinical Physiology at Ghaem Medical Centre, Mashhad University of Medical Sciences. Over the years, Dr. Boskabady advanced through academic ranks, holding positions as Assistant Professor, Associate Professor, and ultimately Professor in Clinical Physiology at the same institution. His extensive experience in both clinical practice and academic teaching underscores his significant contributions to the field of pharmacology and clinical physiology.

Awards

Dr. Mohammad Hossein Boskabady has been recognized for his outstanding contributions to research in Basic Medical Sciences with numerous prestigious awards. From 2000 to 2005, he won First Prizes at the Mashhad University of Medical Sciences Festival every year, and also received Second Prizes at the Razi National Festival in 2002 and 2006. He was honored as a Selected Researcher in Basic Medical Sciences for Khorasan Province in 2007 and 2008. Dr. Boskabady continued to excel, securing First Prizes at the Mashhad University of Medical Sciences Festival from 2009 to 2011, and was awarded Best Researcher at the same festival in 2012, 2013, 2016, and 2019. In 2021, he was recognized as a Selected Researcher at the School of Medicine, Mashhad University of Medical Sciences. Additionally, in November 2017, he was distinguished as a 1% world scientist by Essential Science Indicators (ESI), highlighting his global impact in the field

Official Posts

Dr. Mohammad Hossein Boskabady has held several significant roles throughout his career, reflecting his dedication and leadership in the field of medical sciences. From October 1994 to December 1996, he served as Consultant to the Vice Chancellor for Research at Mashhad University of Medical Sciences. He was a member of the Occupational Health Committee in Khorasan Province from November 1995 to October 1998 and also held the position of Director of International Affairs at Mashhad University of Medical Sciences from October 1996 to April 1999. Additionally, Dr. Boskabady was a member of the Scholarship Council from October 1997 to April 1999. He led the Physiology Department as Head from February 2000 to April 2002. Dr. Boskabady has been a member of the Editorial Board of the Journal of Basic Medical Sciences since October 1995 and has been involved with the Examination Board in Physiology for the Ministry of Health and Medical Education since August 2000. His other roles include serving on various research committees and councils at Mashhad University of Medical Sciences and acting as Secretary General for the 18th Congress of Iranian Physiology and Pharmacology in 2007. Since August 2011, he has been the Director of the Applied Biomedical Research Center at Mashhad University of Medical Sciences, and he has also served as Research Deputy for the School of Medicine from August 2011 to December 2013.

Publication Top Notes
  • Boskabady, M. H., & Snashall, P. D. (1992). Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree: Evidence for increased drug delivery in asthma. American Review of Respiratory Disease, 145(5), 756-761. DOI: 10.1164/ajrccm/145.5.756.
  • Boskabady, M. H., & Snashall, P. D. (1996). Short term variation of atropine blockade in the tracheobronchial tree of asthmatic subjects. Medical Journal of the Islamic Republic of Iran, 10(3), 183-189. DOI: 10.17102/mjiri.1996.0108.
  • Boskabady, M. H., & Snashall, P. D. (1997). Enhanced histamine H1 receptor blockade with chlorpheniramine in the asthmatic tracheobronchial tree: Further evidence for increased drug delivery in asthma. Medical Journal of the Islamic Republic of Iran, 11(2), 115-122. DOI: 10.17102/mjiri.1997.0063.
  • Boskabady, M. H., & Shhabi, M. (1997). Bronchodilatory and anticholinergic effects of Nigella sativa on isolated guinea pig tracheal chains. Iranian Journal of Medical Sciences, 22(4), 127-133. DOI: 10.30476/ijms.1997.0549.
  • Boskabady, M. H., Rakhshandah, H., & Moetamedshariati, V. (1998). Bronchodilatory and anticholinergic effects of Carum copticum on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 11(5), 329-334. DOI: 10.17102/mjiri.1998.0134.
  • Boskabady, M. H., & Harati, M. (1998). Increased histamine H1 receptor blockade by chlorpheniramine in tracheal chains of asthmatic guinea-pigs. Medical Journal of the Islamic Republic of Iran, 12(2), 265-271. DOI: 10.17102/mjiri.1998.0089.
  • Boskabady, M. H., & Talebi, M. (1999). Bronchodilatory and anticholinergic effects of Carum carvi on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 12(3), 345-351. DOI: 10.17102/mjiri.1999.0154.
  • Boskabady, M. H., & Adel-Kardan, S. (1999). Increased muscarinic receptor blockade by atropine in tracheal chains of ovalbumin-sensitized guinea-pigs. Pharmacology, 58(6), 300-308. DOI: 10.1159/000029652.
  • Boskabady, M. H., & Shikhi, J. (2000). Inhibitory effect of Carum copticum on histamine (H1) receptors of isolated guinea pig tracheal chains. Journal of Ethnopharmacology, 69(2), 217-227. DOI: 10.1016/S0378-8741(99)00244-3.
  • Boskabady, M. H., & Simaei, N. (1999). Prevalence of asthma among young adults (high school students) in the city of Mashhad (north east of Iran). Iranian Journal of Medical Sciences, 24(1), 48-52. DOI: 10.30476/ijms.1999.0442.
  • Boskabady, M. H., & Snashall, P. D. (2000). Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta blockade in asthma. Respirology, 5(2), 111-118. DOI: 10.1046/j.1440-1843.2000.00243.x.
  • Boskabady, M. H., & Moemeni, A. (2000). Stimulatory effect of Carum copticum on beta2 adrenoceptors of isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 13(3), 273-278. DOI: 10.17102/mjiri.2000.0192.
  • Boskabady, M. H., Karbandy, S., & Abedinzadah, A. (2000). The effects of arterial O2 saturation and heart rate on blood pressure. Medical Journal of the Islamic Republic of Iran, 14(2), 37-41. DOI: 10.17102/mjiri.2000.0200.
  • Boskabady, M. H., & Karimian, M. (2000). Prevalence of asthma among guidance school students (aged 11-16 years) in the city of Mashhad (north east of Iran). Archives of Iranian Medicine, 3(3), 165-169. DOI: 10.30476/aim.2000.0109.
  • Boskabady, M. H., & Hosaini, M. (2000). Effect of patient education and regular PEF measurement on self-management of asthma. Iranian Journal of Allergy, Asthma, and Immunology, 1(2), 159-164. DOI: 10.30476/ijaai.2000.0111.
  • Boskabady, M. H., & Ramazani, M. (2001). Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). Journal of Ethnopharmacology, 74(1), 83-88. DOI: 10.1016/S0378-8741(00)00382-5.
  • Boskabady, M. H., Keshmiri, M., Banihashemi, B., & Anvary, K. H. (2002). Lung function values in healthy non-smoking urban adults in Iran. Respiration, 69(4), 320-326. DOI: 10.1159/000065155.
  • Boskabady, M. H., & Klahdoz, G. H. (2002). Prevalence of asthma symptoms among the adult population in the city of Mashhad (north-east of Iran). Respirology, 7(3), 267-272. DOI: 10.1046/j.1440-1843.2002.00413.x.
  • Boskabady, M. H., & Shirmohammadi, B. (2002). Effect of Nigella sativa on isolated guinea pig trachea. Archives of Iranian Medicine, 5(2), 103-107. DOI: 10.30476/aim.2002.0145.
  • Boskabady, M. H., & Shiravi, N. (2002). Inhibitory effect of Nigella sativa on histamine (H1) receptors of isolated guinea pig tracheal chains. Pharmaceutical Biology, 40(8), 596-602. DOI: 10.1076/1388-0209(200208)4008-0005.

Bashige Chiribagula Valentin | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Bashige Chiribagula Valentin | Pharmaceutical Science | Best Researcher Award

Professor of UNILU, Congo.

Dr. Bashige Chiribagula Valentin is a prominent academic and researcher specializing in ethnopharmacology, medicinal chemistry, and quality control. Currently a professor at the University of Lubumbashi, he has held roles including department head, research specialist in pharmacognosy, and educator in pharmacology. His research focuses on the ethnobotanical, phytochemical, and pharmacological properties of medicinal plants, with significant contributions to the development of traditional medicine-based therapies, such as antimalarial and antimicrobial agents. Dr. Chiribagula has led various projects aimed at enhancing the quality and efficacy of herbal remedies and has published extensively in reputed journals. His work includes studies on plant-based treatments for malaria, diabetes, and wound healing, reflecting his commitment to integrating traditional knowledge with modern scientific approaches. His leadership in the academic and scientific community, coupled with his impactful research, underscores his candidacy for the Best Researcher Award.

Profile
Education

Dr. Bashige Chiribagula Valentin’s educational background is extensive and well-rounded. He earned his Doctorate in Pharmaceutical Sciences from the University of Lubumbashi (UNILU) and the Université de Mons (UMONS) in 2021, specializing in Pharmacognosy with a focus on ethnopharmacology. Prior to this, he obtained a Diplôme d’Études Approfondies in Pharmacognosy from UNILU in 2016. His foundational education includes a Diplôme de Pharmacie d’Industrie et Analyse de Médicaments from UNILU, completed in 2012, and a Diplôme d’Études Générales en Sciences Pharmaceutiques from the University of Kinshasa (UNIKIN) in 2006. His academic journey demonstrates a strong commitment to advancing knowledge in pharmaceutical sciences, particularly in the areas of pharmacognosy and ethnopharmacology.

Professional Experience

Dr. Bashige Chiribagula Valentin has an extensive and diverse professional background in the field of pharmacognosy and ethnopharmacology. He has served as a Professor at the University of Lubumbashi since 2022, where he also holds positions as President of juries and Secretary of the Department of Pharmacology. His career at the university began as an Assistant in 2013, progressing to a Chief of Works and Specialist in Pharmacognosy. In addition to his academic roles, Dr. Chiribagula has been actively involved in the pharmaceutical industry as a Quality Control Manager at PROMED Lubumbashi. His research focuses on ethnopharmacology, medicinal chemistry, and quality control of medicinal plants, contributing significantly to the development of traditional medicine projects. Dr. Chiribagula’s career also includes roles in secondary education and civil society, showcasing his dedication to both education and community service.

Research Interest

Dr. Bashige Chiribagula Valentin’s research focuses on the ethnopharmacological and medicinal properties of plants, particularly in the context of traditional medicine. His work spans the study of plant-based remedies for various diseases, including malaria and diabetes, with a strong emphasis on the pharmacognosy of medicinal plants. Dr. Chiribagula’s research integrates ethnobotanical surveys, phytochemical analysis, and pharmacological testing to explore and validate the therapeutic potential of natural substances. His projects include the development of medicinal plants for wound healing, anti-malarial, anti-ulcer, and antibacterial applications. Additionally, he investigates the nutritional and medicinal benefits of indigenous fungi, fruits, and vegetables. His research aims to bridge traditional knowledge with modern scientific validation, contributing to the development of effective, natural therapeutic agents and enhancing the quality of life in the Democratic Republic of Congo.

Research Skills

Dr. Bashige Chiribagula Valentin demonstrates a robust set of research skills essential for advancing his field of study. His expertise spans ethnopharmacology, medicinal chemistry, and quality control, with a strong emphasis on the pharmacognostic and phytochemical evaluation of medicinal plants. Dr. Chiribagula excels in employing various analytical techniques, including chromatography (TLC, Flash, HPLC), spectral analysis (MS), and microbiological assays (antimicrobial testing, antioxidant assays). His proficiency in using statistical software such as SPSS and GraphPad supports his rigorous data analysis. Additionally, he has a solid background in experimental design and execution, demonstrated by his work on traditional medicine and natural product research. His ability to integrate traditional knowledge with scientific methodologies underscores his contributions to the development of novel therapeutic agents and quality control measures in pharmaceuticals. Dr. Chiribagula’s comprehensive approach and methodological skills are integral to his research successes.

Awards and Recognition

Dr. Bashige Chiribagula Valentin has garnered significant recognition for his contributions to pharmacognosy and ethnopharmacology. He was honored as the “Major de Promotion” in 2012 and achieved notable accolades in 2019, securing first place at the MT180 regional AUF competition and second place at the national MT180 competition. His scholarly excellence is highlighted by his award-winning research on ethnobotanical studies and medicinal plants, which has been recognized in several prestigious journals. Dr. Chiribagula’s impactful work in the development of medicinal plant-based treatments, including those for malaria and wound healing, has further solidified his reputation in the scientific community. These awards underscore his dedication to advancing knowledge in pharmaceutical sciences and his commitment to improving public health through innovative research.

Conclusion

Bashige Chiribagula Valentin is a strong candidate for the Research for Best Researcher Award due to his substantial contributions to ethnopharmacology, his significant publications, and his active role in academia and the pharmaceutical industry. His expertise in traditional medicine and his impactful research on medicinal plants, coupled with his notable awards and professional experience, underline his qualifications for the award.

Publications Top Notes

  • Ethnomedical Knowledge of Plants Used in Nonconventional Medicine for Wound Healing in Lubumbashi, Haut‐Katanga Province, DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2024
  • Ethnomedicinal Knowledge of Plants Used in Nonconventional Medicine in the Management of Diabetes Mellitus in Kinshasa (Democratic Republic of the Congo)
    • Authors: Bashige Chiribagula Valentin
    • Year: 2023
  • Ethnobotanical study of plants used by traditional healers in Lubumbashi (Democratic Republic of Congo) in the management of typhoid fever
    • Authors: Bashige Chiribagula Valentin
    • Year: 2022
  • Activité antioxydante de 53 plantes réputées antimalariques en République Démocratique du Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • In vitro antioxidant activity and in vivo aphrodisiac activity in male Cavia porcellus of Albizia adianthifolia (Schum.) W. Wight and Pericopsis angolensis (Baker) Meeuwen
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Knowledge, attitudes and practices among the population, towards COVID-19 in the Lubumbashi city (DR Congo): An online cross-sectional survey
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Mineral elements analysis and total flavonoids content in the fresh leaves from two varieties of Hibiscus sabdariffa L. consumed as vegetable in Lubumbashi (DR Congo)
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Antimicrobial, antioxidant activities and toxicity on Cavia porcellus of Dialium angolense Welw. Ex Oliv, a traditional medicinal plant from Bagira in Eastern of DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020
  • Ethnobotanical study of medicinal plants used in the treatment of sexual dysfunctions in traditional medicine in Kampemba-Lubumbashi, DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020
  • Antiplasmodial, antioxidant and toxicological study of leaves extracts of Dalbergia katangensis Lecheneaud (Fabaceae) from Eastern DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020